Premium
Sudden ventricular fibrillation and death during ibrutinib therapy—A case report
Author(s) -
Bernardeschi Paolo,
Pirrotta Maria Teresa,
Del Rosso Attilio,
Fontanelli Giulia,
Milandri Carlo
Publication year - 2019
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13290
Subject(s) - ibrutinib , medicine , mantle cell lymphoma , atrial fibrillation , ventricular fibrillation , adverse effect , cardiology , lymphoma , oncology , refractory (planetary science) , chronic lymphocytic leukemia , leukemia , physics , astrobiology
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase approved for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and refractory Waldenstrom's disease. It increases progression‐free survival, overall survival, response rate. The most frequent adverse reactions, are increased risk in of bleeding and atrial fibrillation, but several reports of more dangerous rhythm disturbances have been recently reported in literature. A case of a patient with refractory Waldenstrom's disease, who developed ventricular fibrillation while taking ibrutinib, is reported, along with a concise literature review.